Editas Medicine Inc

Most Recent

  • uploads///investor for construction project
    Personal Finance

    Stocks versus ETFs: Which Should Investors Choose?

    Every investor faces some tough choices. Should you turn to stocks, exchange-traded funds (ETFs), index funds, mutual funds, or bonds?

    By Aran Davies
  • uploads///south dakota cannabis
    Cannabis

    South Dakota Plans for Marijuana Legalization amid COVID-19

    Marijuana is illegal in South Dakota. However, the state decided to make both recreational and medical marijuana legal this year.

    By Sushree Mohanty
  • uploads///canopy growth up
    Cannabis

    Canopy Growth Might Impress Investors with Its Q4 Earnings

    Canopy Growth (NYSE:CGC)(TSE:WEED) will likely report its results for the fourth quarter of fiscal 2020 on May 29 before the market opens.

    By Sushree Mohanty
  • uploads///medmen recovery
    Cannabis

    Did MedMen’s Q3 Earnings Start a Path to Recovery?

    MedMen released its results for the third quarter of fiscal 2020 on May 27. The stock declined 4.0% and closed at $0.35 on the OTC markets.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Macroeconomic Analysis

    S&P 500: Could December Outlook Be Like 2018?

    In November, the S&P 500 Index (SPY) rose 3.4%—the highest monthly gain since June. Notably, in December 2018, the S&P 500 Index lost 9.2%.

    By Rabindra Samanta
  • Oil Prices
    Energy & Utilities

    Will Oil Prices Feel the Heat of the Impeachment Inquiry?

    At 10:21 AM ET, WTI crude oil prices were up 1.6%. If they stay at this level, we could see the second consecutive weekly rise for oil prices.

    By Rabindra Samanta
  • uploads///nebraska marijuana
    Cannabis

    Marijuana Legalization Hopes Rise in Nebraska for 2020

    Marijuana legalization hopes never really ended in Nebraska. Signature gathering paused in the state amid the pandemic and the lockdown.

    By Sushree Mohanty
  • uploads///aurora cannabis revision march
    Cannabis

    Analysts Revise Estimates for Aurora Cannabis in March

    Analysts are skeptical due to Aurora Cannabis’s recent string of bad news. The stock could get delisted. However, analysts still have hope for the company.

    By Sushree Mohanty
  • uploads///new york marijuana
    Cannabis

    Marijuana Legalization Won’t Happen in New York in 2020

    New York lawmakers decided to delay marijuana legalization due to the COVID-19 pandemic. As a result, New York won’t see marijuana legalization in 2020.

    By Sushree Mohanty
  • uploads///cronos group analysts bearish
    Cannabis

    Cronos Group: Wall Street Is Bearish after Its Earnings

    Cronos Group (NASDAQ:CRON) disappointed investors with its fourth-quarter results on March 30. The company’s revenue was way below analysts’ estimates.

    By Sushree Mohanty
  • uploads///hexo stock rose delisting
    Cannabis

    Hexo Stock Rose, Will It Still Get Delisted?

    Hexo (TSE:HEXO) stock closed 41.3% higher on March 26. So far this week, the stock has risen 59.2%. Hexo faced getting delisted from the exchange.

    By Sushree Mohanty
  • uploads///cannabis companies aid
    Cannabis

    Cannabis Sector Won’t Get Business Relief amid COVID-19

    Since marijuana isn’t legal at the federal level, the cannabis sector won’t get any business relief or help during emergencies.

    By Sushree Mohanty
  • uploads///marijuana essential
    Cannabis

    COVID-19 Pandemic Made Marijuana an Essential Item

    Amid the coronavirus pandemic, marijuana has become an essential item in many US states. As a result, there was a surge in cannabis demand.

    By Sushree Mohanty
  • uploads///aphria analysts bullish
    Cannabis

    Wall Street Has a Bullish Outlook for Aphria in March

    Aphria (NYSE:APHA) is one of the cannabis stocks that investors and analysts still like. They’re confident that the stock will outperform.

    By Sushree Mohanty
  • uploads///marijuana
    Cannabis

    New York Senator Wants to Delay Marijuana Legalization

    New York Senator Liz Krueger thinks that the state needs to deal with the coronavirus pandemic. The state doesn’t need to rush marijuana legalization.

    By Sushree Mohanty
  • uploads///marijuana federal aid
    Cannabis

    Coronavirus: Marijuana Industry Asks for Federal Business Relief

    Currently, the cannabis industry has pleaded with the federal government to help cannabis businesses during these distressing times.

    By Sushree Mohanty
  • uploads///hexo current storm
    Cannabis

    Hexo Stock Faces a Storm, Will It Rebound?

    Hexo (TSE:HEXO) closed with a loss of 19% on March 18. The stock started its downward trend on Tuesday. The company decided to delay its second-quarter earnings.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Energy & Utilities

    Did Analysts Predict Oil Prices Right in 2019?

    So far in 2019, WTI and Brent crude oil spot prices have averaged $56.9 per barrel and $64.3 per barrel. The prices are lower than the average expectations.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Energy & Utilities

    S&P 500 Stocks: Analysts Bullish on Diamondback

    Diamondback Energy (FANG) has the second-highest percentage of “buy” ratings among the constituents of the S&P 500 Index (SPY). Here’s why.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Energy & Utilities

    OPEC+ Meeting: Will Oil Prices Hit $100?

    Today at 7:25 AM ET, US crude oil prices have fallen by 0.5%. According to CNBC, OPEC+ members might increase the current production cut by 0.5 MMbpd.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Financials

    Dow Jones: November Was Its Best Month since June

    This week, the Dow Jones Industrial Average Index (DJI) rose 1%. On a month-to-date basis, it has risen 3.8% and heading for the biggest gain since June.

    By Rabindra Samanta
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///flasks _
    Company & Industry Overviews

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.

    By Daniel Collins
  • uploads///CRSP
    Company & Industry Overviews

    How CRISPR Therapeutics Is Positioned in September

    CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///EDIT
    Earnings Report

    Why Editas Medicine Stock Fell in July

    Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% year-over-year in the second quarter.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///EDIT
    Company & Industry Overviews

    Exploring Editas Medicine’s Research Pipeline

    Editas Medicine’s core capability in genome editing makes use of CRISPR technology to create molecules that can specifically edit DNA.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.